Literature DB >> 18273575

Acute coronary syndromes: management and secondary prevention.

Peter Wenaweser1, Stephan Windecker.   

Abstract

Acute coronary syndromes represent a broad spectrum of ischemic myocardial events including unstable angina, non-ST elevation myocardial infarction and acute ST elevation myocardial infarction, which are associated with high morbidity and mortality. They constitute the most frequent cause of hospital admission related to cardiac disease. Early diagnosis and risk stratification are essential for initiation of optimal medical and invasive management. Therapeutic measures comprise aggressive antiplatelet, antithrombotic, and anti-ischemic agents. In addition, patients with high-risk features, notably positive troponin, ST segment changes and diabetes, benefit from an early invasive as compared to a conservative strategy. Importantly, lifestyle interventions, modification of the risk factor profile, and long-term medical treatment are of pivotal importance in reducing the long-term risk of recurrence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18273575     DOI: 10.1007/s00059-008-3078-4

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  4 in total

Review 1.  [Acute thoracic pain: Chest Pain Unit - the certification campaign of the German Society of Cardiology].

Authors:  Frank Breuckmann; Felix Post; Raimund Erbel; Thomas Münzel
Journal:  Herz       Date:  2009-05       Impact factor: 1.443

2.  [Acute coronary syndromes without ST segment elevation].

Authors:  Helge Möllmann; Holger Nef; Christian W Hamm
Journal:  Herz       Date:  2009-02       Impact factor: 1.443

Review 3.  An historical approach to the diagnostic biomarkers of acute coronary syndrome.

Authors:  Elisa Danese; Martina Montagnana
Journal:  Ann Transl Med       Date:  2016-05

Review 4.  Enzymology of NAD+ homeostasis in man.

Authors:  G Magni; A Amici; M Emanuelli; G Orsomando; N Raffaelli; S Ruggieri
Journal:  Cell Mol Life Sci       Date:  2004-01       Impact factor: 9.261

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.